ArticleJournal of cardiothoracic surgery2026
The role of HIF-1α in rat coronary atherosclerosis through the IL-6/JAK1/STAT3 pathway.
Article in Journal of cardiothoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo explore the protective mechanism of HIF-1α on coronary atherosclerosis (CA) through the IL-6/JAK1/STAT3 pathway.
methodsForty rats were randomly divided into control group, model group, OE HIF-1α group, and shRNA HIF-1α group. The morphology of coronary arteries, ROS fluorescence intensity, measure myocardial enzyme spectrum, and serum biochemical indicators were observed. The expression of HIF-1α, IL-6/JAK1/STAT3 proteins in myocardial tissue was detected by Western blot.
resultsCompared to controls, CA model rats exhibited significantly increased HIF-1α expression (1.7-fold in serum, 2.5-fold in myocardium), elevated ROS levels (2.1-fold), activated IL-6/JAK1/STAT3 pathway (3.2-fold), and coronary artery dilation (79% wider), alongside worsened myocardial enzymes and serum lipids (all P < 0.05); HIF-1α knockdown reversed these changes, reducing HIF-1α by 35%, ROS by 40%, pathway activity by 50%, and coronary diameter by 25%, while HIF-1α overexpression exacerbated all parameters with 2.8-fold higher HIF-1α, 90% increased ROS, and 3.5-fold pathway activation (all P < 0.01).
conclusionHIF-1α knockdown attenuates CA by suppressing IL-6/JAK1/STAT3, reducing oxidative stress and vascular remodeling, while overexpression worsens outcomes. These findings highlight HIF-1α as a potential therapeutic target for CA, suggesting that its inhibition could mitigate myocardial injury in ischemic heart disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.